The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases (NDDs) represent a huge social burden, particularly in Alzheimer's disease (AD) in which all proposed treatments investigated in murine models have failed during clinical trials (CTs). Thus, novel therapeutic strategies remain crucial. Neuroinflammation is a common pathogenic feature of NDDs. As purinergic P2X7 receptors (P2X7Rs) are gatekeepers of inflammation, they could be developed as drug targets for NDDs. Herein, we review this challenging hypothesis and comment on the numerous studies that have investigated P2X7Rs, emphasizing their molecular structure and functions, as well as their role in inflammation. Then, we elaborate on research undertaken in the field of medicinal chemistry to determine potential P2X7R antagonists. Subsequently, we review the state of neuroinflammation and P2X7R expression in the brain, in animal models and patients suffering from AD, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and retinal degeneration. Next, we summarize the in vivo studies testing the hypothesis that by mitigating neuroinflammation, P2X7R blockers afford neuroprotection, increasing neuroplasticity and neuronal repair in animal models of NDDs. Finally, we reviewed previous and ongoing CTs investigating compounds directed toward targets associated with NDDs; we propose that CTs with P2X7R antagonists should be initiated. Despite the high expectations for putative P2X7Rs antagonists in various central nervous system diseases, the field is moving forward at a relatively slow pace, presumably due to the complexity of P2X7Rs. A better pharmacological approach to combat NDDs would be a dual strategy, combining P2X7R antagonism with drugs targeting a selective pathway in a given NDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
How neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967 · cited 1×
“levels of inflammatory mediators present in the parenchyma of the brain or spinal cord in patients with NNDs; in the long term, this low inflammatory status leads to synaptic dysfunction, loss of synapses, and neuronal death.(142)”
BackgroundBurnstock, G. (1972) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06930-3 · Cited by 1,852
The Cytolytic P 2Z Receptor for Extracellular ATP Identified as a P 2X Receptor (P2X 7 )
Surprenant, A., Rassendren, F., Kawashima, E., North, R. A., & Buell, G. (1996) · Science · doi:10.1126/science.272.5262.735 · Cited by 1,739 · cited 10×
“This response was attributed to a specific type of membrane receptors of the purinergic type, initially labeled P2Z,(33) and later identified as P2X7Rs.(34) In the 1990s, P2Z/P2X7 activation was involved in the release of interleukin‐1β (IL‐1β), as well as macrophage communication and differentiation.”
BackgroundInfluentialCost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Neuroinflammation: The Devil Is in the Details
DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640 · cited 19×
“BBG has been utilized in both in vitro and in vivo experiments; however, this compound also targets P2X4, P2X5, rat P2Y1, and P2Y2 receptors, as well as voltage‐gated sodium channels.8,95,96 BBG was initially the main compound used for the proof‐ of‐concept of P2X7Rs role in NDDs, such as ALS and AD.97–99 Its permeabi…”
BackgroundInfluential-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446 · cited 1×
“Furthermore, the accumulation of oligomerized α‐synuclein is postulated to mediate neurotoxicity by activating microglia, followed by the production of ROS and proinflammatory mediators.(167) Importantly, α‐synuclein binds to P2X7Rs in microglia and stimulates P2X7R transcription,(168) thus explaining the upregulation…”
BackgroundActivation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445 · cited 2×
“This intracellular K drop is possibly the best‐established mechanism underlying P2X7R‐mediated formation of the NLRP3 inflammasome.(77)”
BackgroundThe P2X7 Receptor in Infection and Inflammation
Di Virgilio, F., Dal Ben, D., Sarti, A. C., Giuliani, A. L., & Falzoni, S. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.020 · Cited by 1,267 · cited 19×
“BBG has been utilized in both in vitro and in vivo experiments; however, this compound also targets P2X4, P2X5, rat P2Y1, and P2Y2 receptors, as well as voltage‐gated sodium channels.8,95,96 BBG was initially the main compound used for the proof‐ of‐concept of P2X7Rs role in NDDs, such as ALS and AD.97–99 Its permeabi…”
BackgroundInfluentialMulti-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain
Alliot, F., Godin, I., & Pessac, B. (1999) · Developmental Brain Research · doi:10.1016/s0165-3806(99)00113-3 · Cited by 884 · cited 1×
“Furthermore, there exists an interesting hypothesis based on the fact that microglia have the same progenitor origin as macrophages.(143) Glial cells exhibit a low overall turnover rate(144,145); this may explain why glial cells are susceptible to potential proinflammatory effects of age, injury, stress, or NDDs.”
BackgroundRetinal degeneration mutants in the mouse
Chang, B., Hawes, N. L., Hurd, R. E., Davisson, M. T., Nusinowitz, S., & Heckenlively, J. R. (2002) · Vision Research · doi:10.1016/s0042-6989(01)00146-8 · Cited by 840
Regulation of learning and memory by meningeal immunity: a key role for IL-4
Derecki, N. C., Cardani, A. N., Yang, C. H., Quinnies, K. M., Crihfield, A., Lynch, K. R., & Kipnis, J. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091419 · Cited by 800
Parvathenani, L. K., Tertyshnikova, S., Greco, C. R., Roberts, S. B., Robertson, B., & Posmantur, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209478200 · Cited by 488 · cited 8×
“BBG has been utilized in both in vitro and in vivo experiments; however, this compound also targets P2X4, P2X5, rat P2Y1, and P2Y2 receptors, as well as voltage‐gated sodium channels.8,95,96 BBG was initially the main compound used for the proof‐ of‐concept of P2X7Rs role in NDDs, such as ALS and AD.97–99 Its permeabi…”
BackgroundInfluentialA robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00068 · Cited by 451
Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP
Karmakar, M., Katsnelson, M. A., Dubyak, G. R., & Pearlman, E. (2016) · Nature Communications · doi:10.1038/ncomms10555 · Cited by 450
The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
Savio, L. E. B., de Andrade Mello, P., da Silva, C. G., & Coutinho-Silva, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00052 · Cited by 437 · cited 2×
“This supports the view that P2X7R blockers could have a role in preventing or improving MS symptoms.(23)”
BackgroundCuenca, N., Fernández-Sánchez, L., Campello, L., Maneu, V., De la Villa, P., Lax, P., & Pinilla, I. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.07.001 · Cited by 401
Self-citationP2X7 receptor: an emerging target in central nervous system diseases
Sperlágh, B., & Illes, P. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.08.002 · Cited by 390
The P2X7 receptor: A main player in inflammation
Adinolfi, E., Giuliani, A. L., De Marchi, E., Pegoraro, A., Orioli, E., & Di Virgilio, F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.021 · Cited by 385 · cited 5×
“(ii) P2X7R activation promotes intracellular Ca increase, which in turn activates nuclear factor kappa B (NF‐κB), which is then translocated into the nucleus eliciting the activation of immature pro‐IL‐1β transcription; next, caspase 1 catalyzes the conversion to mature IL‐1β, which can be subsequently released to the…”
BackgroundInfluentialTan, E., Ding, X.-Q., Saadi, A., Agarwal, N., Naash, M. I., & Al-Ubaidi, M. R. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-1114 · Cited by 345 · cited 1×
“The photoreceptor derived 661W cell line is a mouse photoreceptor‐derived cell line, obtained from a retinal tumor formed in a transgenic mouse expressing SV40 large T‐antigen under the control of the human interphotoreceptor retinoid‐binding protein promoter.(243,257) This cell line has been used to study cytotoxicit…”
BackgroundNeuroinflammation in Neurodegenerative Disorders-a Review
Schain, M., & Kreisl, W. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0733-2 · Cited by 301
Activation of Microglia by Amyloid β Requires P2X7 Receptor Expression
Sanz, J. M., Chiozzi, P., Ferrari, D., Colaianna, M., Idzko, M., Falzoni, S., Fellin, R., Trabace, L., & Di Virgilio, F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803612 · Cited by 293
McLarnon, J. G., Ryu, J. K., Walker, D. G., & Choi, H. B. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240470.97295.d3 · Cited by 281
Reanalysis of P2X7Receptor Expression in Rodent Brain
Sim, J. A., Young, M. T., Sung, H.-Y., North, R. A., & Surprenant, A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1469-04.2004 · Cited by 264 · cited 1×
“receptor was knocked out in these strains, thus suggesting that antibodies may be detecting splice variants that escaped deletion.(151,152) Therefore, caution is warranted with data interpretation from in vivo studies utilizing these”
BackgroundNucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity
Fowler, B. J., Gelfand, B. D., Kim, Y., Kerur, N., Tarallo, V., Hirano, Y., Amarnath, S., Fowler, D. H., Radwan, M., Young, M. T., et al. (2014) · Science · doi:10.1126/science.1261754 · Cited by 225
The microglial ATP‐gated ion channel P2X7 as a CNS drug target
Bhattacharya, A., & Biber, K. (2016) · Glia · doi:10.1002/glia.23001 · Cited by 221 · cited 18×
“BBG has been utilized in both in vitro and in vivo experiments; however, this compound also targets P2X4, P2X5, rat P2Y1, and P2Y2 receptors, as well as voltage‐gated sodium channels.8,95,96 BBG was initially the main compound used for the proof‐ of‐concept of P2X7Rs role in NDDs, such as ALS and AD.97–99 Its permeabi…”
BackgroundInfluentialP2X7 Interactions and Signaling – Making Head or Tail of It
Kopp, R., Krautloher, A., Ramírez-Fernández, A., & Nicke, A. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00183 · Cited by 217
K+ regulates Ca2+ to drive inflammasome signaling: dynamic visualization of ion flux in live cells
Yaron, J. R., Gangaraju, S., Rao, M. Y., Kong, X., Zhang, L., Su, F., Tian, Y., Glenn, H. L., & Meldrum, D. R. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.277 · Cited by 212 · cited 1×
“In addition, Na influx accompanied by water influx diminishes the cytosolic K concentration below the threshold, leading to inflammasome activation.(79) Notably, reactive oxygen species (ROS) induce inflammasome aggregation and IL‐1β release, secondary to P2X7R activation.”
BackgroundP2X4 receptor controls microglia activation and favors remyelination in autoimmune encephalitis
Zabala, A., Vazquez‐Villoldo, N., Rissiek, B., Gejo, J., Martin, A., Palomino, A., Perez‐Samartín, A., Pulagam, K. R., Lukowiak, M., Capetillo‐Zarate, E., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708743 · Cited by 192
Tsunoda, I., & Fujinami, R. S. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199606000-00001 · Cited by 184
Neuronal P2X7 Receptors Revisited: Do They Really Exist?
Illes, P., Khan, T. M., & Rubini, P. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3103-16.2017 · Cited by 179
Phagocytic glial cells: sculpting synaptic circuits in the developing nervous system
Schafer, D. P., & Stevens, B. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.09.012 · Cited by 174
Block of purinergic P2X7 receptor is neuroprotective in an animal model of Alzheimer's disease
Ryu, J. K., & McLarnon, J. G. (2008) · NeuroReport · doi:10.1097/wnr.0b013e3283179333 · Cited by 134
P2X7 receptor is critical in α-synuclein–mediated microglial NADPH oxidase activation
Jiang, T., Hoekstra, J., Heng, X., Kang, W., Ding, J., Liu, J., Chen, S., & Zhang, J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.03.015 · Cited by 123
Recent advances in CNS P2X7 physiology and pharmacology: Focus on neuropsychiatric disorders
Bhattacharya, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00030 · Cited by 115
Marcellino, D., Suárez-Boomgaard, D., Sánchez-Reina, M. D., Aguirre, J. A., Yoshitake, T., Yoshitake, S., Hagman, B., Kehr, J., Agnati, L. F., Fuxe, K., et al. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0400-0 · Cited by 97 · cited 9×
“However, CTs with NSAIDs have provided negative outcomes in AD and PD. (5) The proof‐of‐concept in animal models of familial or sporadic NDDs is far from consistent: the chronic administration of a P2X7R antagonist is yet to provide a clear picture of efficacy.”
BackgroundResultInfluentialInflammatory Pathways in Parkinson’s Disease; A BNE Microarray Study
Durrenberger, P. F., Grünblatt, E., Fernando, F. S., Monoranu, C. M., Evans, J., Riederer, P., Reynolds, R., & Dexter, D. T. (2012) · Parkinson's Disease · doi:10.1155/2012/214714 · Cited by 63
Wilkaniec, A., Gąssowska, M., Czapski, G. A., Cieślik, M., Sulkowski, G., & Adamczyk, A. (2017) · Purinergic Signalling · doi:10.1007/s11302-017-9567-2 · Cited by 61 · cited 1×
“In contrast, ATP release induced by stimulation of SH‐SY5Y cells was mediated by direct activation of P2X7Rs by α‐synuclein.(165) Both postmortem analysis of brain tissue from PD patients and in vivo experiments in animal models of PD support the association”
Cited by
Inflamed brain: Targeting immune changes and inflammation for treatment of depression
Sakamoto, S., Zhu, X., Hasegawa, Y., Karma, S., Obayashi, M., Alway, E., & Kamiya, A. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13286 · Cited by 51
D’Amico, R., Fusco, R., Siracusa, R., Impellizzeri, D., Peritore, A. F., Gugliandolo, E., Interdonato, L., Sforza, A. M., Crupi, R., Cuzzocrea, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126471 · Cited by 51
“This is understandable, considering that P2X7Rs are expressed by immune and inflammatory cells and are upregulated in inflammatory processes, including mast cells, dendritic cells and microglia, the most widely studied cells from the monocyte/macrophage axis [29].”
BackgroundIn Situ Detection of Neuroinflammation Using Multicellular 3D Neurovascular‐Unit‐on‐a‐Chip
Choi, J., Choi, H. K., & Lee, K. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202304382 · Cited by 21
Metadata
- Authors
- Calzaferri, F., Ruiz‐Ruiz, C., de Diego, A. M. G., de Pascual, R., Méndez‐López, I., Cano‐Abad, M. F., Maneu, V., de los Ríos, C., Gandía, L., & García, A. G.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2020-07-16
- Volume
- 40
- Issue
- 6
- Pages
- 2427-2465
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W3042775141
- Cited by
- 97
- References
- 40
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.